Expanding Into Southeast Asia: Which Market Should You Enter First?

The standard advice is "start with Singapore." The reasoning is usually: English-language, highly organized regulatory system, abridged routes for devices already approved by the FDA, an EU notified body and other reference regulators, serves as a regional hub, and you can use the Singapore registration to support other ASEAN markets later. This advice is not wrong. But it's also not universally right, and following it mechanically without considering your specific situation can lead to suboptimal sequencing.

Here's a framework for thinking through the market entry sequence question with the variables that actually matter.

Device regulation changes, once a month. One email, with the dates to plan around.

The Singapore-first case: when it makes sense

Singapore-first makes the most sense when:

Your device is high-risk (Class C/D equivalent). High-risk devices require the most rigorous regulatory review everywhere. Singapore's HSA, while rigorous, is faster and more predictable than Indonesia's Ministry of Health, Malaysia's MDA or the Thai FDA for Class C/D-equivalent devices. Getting through Singapore establishes a regional track record and sometimes supports other market applications. If you're going to have a 12-month review somewhere anyway, Singapore is the one with the most reliable timeline and the most legible process.

You need regional clinical evidence. Singapore's hospitals are sophisticated and produce publication-quality clinical data. A clinical study conducted in Singapore — at National University Hospital, Singapore General Hospital, or one of the major private hospital groups — carries weight when submitting to other Asian regulators. If your market entry strategy involves building a regional clinical evidence base, Singapore is the place to start generating it.

Your team has limited Asia experience. Singapore's regulatory environment is the most similar to Western regulatory environments (organized, English, rule-based, transparent). For companies building their Asia regulatory muscle for the first time, Singapore is a reasonable place to learn the system before handling more complex markets.

You're building a regional hub strategy. If your commercial model involves Singapore as a regional headquarters with distribution managed from there, it's logical to establish regulatory presence there first.

The case against Singapore-first

Singapore has 5.9 million people. It's a wealthy country with sophisticated healthcare — but it's not where the volume is. For most medical device categories, Singapore will not be a major revenue market in absolute terms. The revenue potential in Indonesia (280 million people), Vietnam (100 million people), and Thailand (70 million people) dwarfs Singapore.

A Singapore registration does not transfer to Indonesia: it needs its own registration. Malaysia and Thailand are different. Malaysia's conformity assessment bodies verify an HSA registration instead of carrying out a full assessment, in 30 working days instead of 60, and Thailand lists HSA among the foreign agencies whose approvals it accepts. A company that spends 12 months getting Singapore right and then needs another 12–18 months for Indonesia has spent 2–3 years before accessing the largest market in the region.

For companies with resource constraints — which includes most companies that aren't already large multinationals — Singapore-first can delay meaningful revenue access.

The Indonesia-first case: when it makes sense

Indonesia is the largest market in Southeast Asia by population and arguably by long-term medical device opportunity. Indonesia's registration process, run by the Ministry of Health, is more complex and slower than Singapore's, but it's navigable with the right local consultant and a well-prepared dossier.

Indonesia-first makes sense when:

Your device is Class A or B. Lower-risk devices have shorter review timelines in Indonesia and less demanding technical documentation requirements. The complexity gap between Indonesia and Singapore is smaller for Class B than for Class C/D. If you can get a Class B device registered in Indonesia in 6–9 months, the calculus changes relative to the Singapore-first model.

Your device addresses a high-volume need. Wound care, disposable consumables, basic diagnostics — categories where Indonesia's volume justifies the regulatory investment even if the per-unit margin is lower than high-risk devices.

Your distributor network is Indonesia-centric. If you've already identified a strong Indonesian distributor with good working relationships at the Ministry of Health's device directorate and a track record of efficient registration management, the practical barriers to Indonesia-first are lower than the theoretical framework suggests.

Corrected 20 October 2026. We named BPOM as Indonesia's device regulator (it is the Ministry of Health); described a Korean FDA/CE recognition pathway that does not exist; listed five Vietnamese reference countries instead of the nine in Decree 98; said a Singapore registration gives no shortcut in Malaysia (it does, since March 2026); and gave an unsourced market-size ranking for Japan, which we removed.

Research what's happening in each market before you decide

See who's registered in each target market, what device classes they filed under, and how quickly new products appear after registration. Use this to calibrate your sequencing decision with real market data. Try it free for 30 days and we will set it up around your products.

Start searching free →

The Japan question

Japan sits outside the Southeast Asia sequencing question but belongs in any serious discussion of Asian market entry. It is also a market where who holds your registration matters more than anywhere else in the region. See our Japan page.

Japan should be in your planning horizon even if it's not your first entry market. The reason: Japan's entry process (PMDA shonin or ninsho, Marketing Authorization Holder establishment) takes the longest of any market covered here. Starting the Japan planning process — or initiating preliminary conversations with potential MAH partners — several years before you expect to sell in Japan is appropriate for high-risk devices.

If Japan is eventually important to your strategy, the sequencing question isn't just about Southeast Asia; it's about resource allocation between the relatively accessible Southeast Asian markets and the high-investment Japan market. Companies that try to do Japan and multiple Southeast Asian markets simultaneously often underresource all of them.

Korea and Vietnam as strategic additions

South Korea has no route that shortens its review because a device is approved in the US or the EU. What carries across is evidence: MFDS accepts test and clinical data evaluated by a regulator in an OECD member country, and an MDSAP certificate turns its quality-system audits into a document review. A well-built US file still saves real work in Korea, but plan Korea as its own review.

Vietnam deserves more attention than it typically gets in market entry conversations. The fast-track route for Class C and D devices already approved in a reference country — Decree 98 lists nine: the US, the EU, the UK, Switzerland, Japan, Australia, Canada, China and South Korea — makes Vietnam accessible for companies with established regulatory credentials. Vietnam's healthcare market is growing quickly and is currently underpenetrated for many device categories. For companies that can leverage the reference pathway, Vietnam can be entered with relatively modest incremental investment.

The research-first framework

Rather than following a standard sequencing heuristic, the better approach is to research what's actually happening in each target market before deciding where to go first:

  1. Check where your direct competitors are registered. If your three main competitors are all in Indonesia but none are in Vietnam, that tells you something about where the commercial opportunity is concentrated. If a competitor just started registering in a market they weren't in before, they've done the analysis — you can benefit from reading their strategic signal.
  2. Look at device category density. How many active registrations exist in your device category in each market? High density means established competitive market. Low density might mean opportunity — or it might mean the market economics don't support the device category.
  3. Assess your device class in each target market. The same device may be classified differently in different markets. Your Class B Indonesia filing might be Class C in Thailand. This classification difference affects the review timeline, the documentation burden, and the overall cost of market entry in each market.
  4. Evaluate your distributor network. Where do you have strong potential distributor relationships? An excellent distributor in Malaysia with good MDA relationships is worth considering even if Malaysia isn't the largest market, because the execution risk is lower.

The recommendation

There is no universally correct answer. The right first market depends on your device class, your distributor relationships, your resource constraints, and the competitive landscape in your specific device category. What the "Singapore first" heuristic gets right is risk management — Singapore is the most legible first step. What it misses is the revenue dimension — Singapore isn't where the volume is, and delaying access to larger markets has real costs.

The companies that execute Asian expansion best are the ones who research the specific market conditions for their specific device — including registration landscape, competitor presence, and commercial infrastructure — before committing to a sequence. Registration data is the fastest way to get that market-specific picture.

Device regulation changes, once a month

What changed across our 31 markets, checked against each authority's own documents, with the dates to plan around. Unsubscribe in one click.

Not sure where to start?

Tell us where you are, and we'll point you to the right first step.

Most companies come to us with one of these four questions. Each one is a conversation, not a form.